Taysha Gene Therapies (TSHA) AI Stock Analysis

• Market Cap: $796.56M
• Dividend Yield: N/A
• Average Volume (3M): 2.73M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.77
• Revenue Growth: -37.09%
• EPS Growth: 58.96%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 272,794,900
• 10 Day Avg. Volume: 2,715,138
• 30 Day Avg. Volume: 2,733,368
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 53.76
• Enterprise Value/Gross Profit: 55.66
• Enterprise Value/Ebitda: -4.75
• 1Y Price Target: $9.00
• Price Target Upside: 216.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 57 Neutral
• Price Target: $3.00 ▲(5.63% Upside)

Taysha Gene Therapies' stock score reflects a challenging financial environment typical of early-stage biotech firms, balanced by strong technical momentum and positive developments in clinical trials and regulatory progress. The company's financial stability is bolstered by a significant cash runway, but ongoing losses and increased expenses present risks.

Positive Factors

Clinical Trials

A 100% responder rate was achieved in Part A of the study, increasing confidence in a positive pivotal outcome.

Financial Performance

The company ended the financial period with $313 million after a substantial financing, indicating strong financial backing.

Product Development

TSHA is developing a gene therapy called TSHA-102 for Rett syndrome, which has the potential to be the first approved disease-modifying therapy.

Negative Factors

Market Risks

There are several risks to the Buy thesis, including long-term efficacy and safety needing validation, public skepticism about gene therapy, and potential competition from other companies.

Strategic Risks

Astellas has the exclusive option to buy the program, which could limit upside.

Taysha Gene Therapies Business Overview & Revenue Model

Company Description

Taysha Gene Therapies (TSHA) is a biotechnology company dedicated to developing and commercializing adeno-associated virus (AAV) gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). The company's mission is to eradicate severe genetic diseases through the power of gene therapy, with a focus on advancing a robust pipeline of therapies aimed at addressing significant unmet medical needs. Taysha leverages its proprietary AAV platform and is committed to transforming the lives of patients affected by debilitating genetic disorders.

How the Company Makes Money

Taysha Gene Therapies primarily generates revenue through the development and commercialization of its gene therapy products. The company seeks to commercialize its therapies either directly or through strategic partnerships and collaborations with other pharmaceutical companies. Revenue can be derived from licensing agreements, milestone payments, and royalties on sales of approved therapies. Additionally, Taysha may receive funding through research and development collaborations or grants from government and non-profit organizations focused on advancing treatments for rare diseases. The company's financial performance is significantly influenced by the success of its clinical trials, regulatory approvals, and the commercial adoption of its therapies.

Taysha Gene Therapies Financial Statement Overview

Summary

Taysha Gene Therapies is facing financial challenges with ongoing losses and declining revenues. The balance sheet shows moderate leverage, but low equity levels signal financial instability. Negative cash flows further highlight liquidity constraints, posing challenges for sustainable growth and profitability.

Income Statement

Taysha Gene Therapies shows persistently negative net income and declining revenues, leading to weak profitability metrics. The company exhibits low EBIT and EBITDA margins and a negative revenue growth trajectory, indicating challenges in achieving operational efficiency and revenue generation.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio and a declining equity base, suggesting financial strain. The equity ratio indicates limited shareholder equity relative to assets. The company's leverage and low equity position present financial stability risks.

Cash Flow

Cash flows are negative, driven by substantial operating losses. The cash flow to net income ratios are unfavorable, pointing to cash management challenges. Limited free cash flow growth indicates potential liquidity issues, despite consistent financing inflows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.10M	8.33M	15.45M	2.50M	0.00	0.00
Gross Profit	7.82M	8.33M	15.45M	2.50M	-492.00K	-9.00K
EBITDA	-91.64M	-87.95M	-105.20M	-159.73M	-172.78M	-59.97M
Net Income	-92.72M	-89.30M	-111.57M	-166.01M	-175.46M	-43.00M
Balance Sheet
Total Assets	333.33M	160.36M	172.73M	126.28M	213.96M	258.88M
Cash, Cash Equivalents and Short-Term Investments	312.76M	139.04M	143.94M	87.88M	149.10M	251.25M
Total Debt	16.81M	63.18M	61.11M	59.93M	63.09M	0.00
Total Liabilities	84.60M	88.84M	97.79M	125.33M	118.57M	7.58M
Stockholders Equity	248.73M	71.53M	74.94M	949.00K	95.38M	251.30M
Cash Flow
Free Cash Flow	-82.54M	-81.60M	-80.39M	-113.26M	-138.60M	-39.81M
Operating Cash Flow	-82.13M	-81.22M	-73.02M	-88.39M	-117.04M	-30.73M
Investing Cash Flow	-331.00K	-363.00K	-7.35M	-24.93M	-21.55M	-9.08M
Financing Cash Flow	222.47M	76.68M	136.39M	52.10M	39.08M	291.06M

Taysha Gene Therapies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSHA, the sentiment is Positive. The current price of 2.84 is below the 20-day moving average (MA) of 2.89, above the 50-day MA of 2.68, and above the 200-day MA of 2.16, indicating a bullish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 54.02 is Neutral, neither overbought nor oversold. The STOCH value of 36.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSHA.

Taysha Gene Therapies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSHA	57 Neutral	$796.56M	―	-51.86%	―	-37.09%	58.96%
GLUE	52 Neutral	$296.44M	14.34	9.81%	―	2990.57%	―
Sector *	51 Neutral	$7.89B	-0.33	-41.61%	2.23%	23.26%	-2.03%
OLMA	46 Neutral	$374.74M	―	-49.72%	―	―	6.82%
TSVT	41 Neutral		―		―	-32.07%	98.22%
RNAC	40 Underperform	$261.32M	―	-938.38%	―	38.82%	-645.78%
MBX	38 Underperform	$506.93M	―	-56.28%	―	―	―

Taysha Gene Therapies Corporate Events

Taysha Gene Therapies Approves Share Increase Amendment

On June 2, 2025, Taysha Gene Therapies, Inc. held its annual meeting of stockholders where an amendment to increase the authorized number of shares of common stock from 400,000,000 to 700,000,000 was approved. Additionally, two directors were elected, and Deloitte & Touche LLP’s appointment as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions reflect the company’s strategic focus on expanding its capital structure and solidifying its governance framework.

Taysha Gene Therapies Announces Major Stock Offering

On May 28, 2025, Taysha Gene Therapies announced an underwriting agreement to sell 46,868,687 shares of common stock and pre-funded warrants for 25,858,586 shares in a public offering, expecting to raise approximately $187.4 million. The offering, managed by Jefferies, BofA Securities, Piper Sandler, and Barclays, aims to fund the company’s operations and capital expenditures into 2028, with the closing expected on May 30, 2025.

Taysha Gene Therapies Announces Pivotal Trial Design for TSHA-102

On May 28, 2025, Taysha Gene Therapies announced the design details for the pivotal Part B trial of TSHA-102 in Rett syndrome, following positive clinical data from Part A of the REVEAL trials. The trial, supported by the FDA, aims to assess developmental milestone gains in patients aged six and above, with the company planning to initiate the pivotal program in the third quarter of 2025. Additionally, Taysha suspended its ATM Prospectus related to $100 million of common stock but maintained the Sales Agreement in effect.